Study Details
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients with Advanced Non-Small Cell Lung Cancer
Clinicaltrials.gov ID
Astellas Study ID
OSI-774-202
EudraCT ID
Dose to Rash
Condition
Non Small Cell Lung Cancer, Advanced/Metastatic Cancer
Phase
Phase 2
Age
18 Years - N/A N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Nov 2003 - Mar 2007
Masking
None (Open Label)
Enrollment number
43
A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer who have Failed Prior Chemotherapy
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients with Advanced Non-Small Cell Lung Cancer? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Institute for Drug Development Cancer Therapy and Research Center
San Antonio, United States, 78229